Rekombinanter IL-6R (Tocilizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter IL-6R (Tocilizumab Biosimilar) Antikörper (ABIN7487791)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Tocilizumab Biosimilar - Anti-IL-6R mAb
-
Produktmerkmale
- Antibody Type: IgG1Kappa
-
Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotyp
- IgG1 kappa
-
-
anti-IL-6R (Tocilizumab Biosimilar) antibody
Research Grade Reaktivität: Human ELISA, FACS Wirt: Humanized Monoclonal unconjugated Recombinant Antibody
anti-IL-6R (Tocilizumab Biosimilar) antibodyReaktivität: Human ELISA, InhA Wirt: Kaninchen Chimeric RhPM-1 unconjugated Recombinant Antibody
-
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Buffer
- PBS pH 7.5
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- 4°C for short term, -20°C for long term
-
-
- IL-6R (Tocilizumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
-
Tocilizumab
Tocilizumab, also known as atlizumab, is a recombinant humanized, anti-human monoclonal antibody (mAb) of the immunoglobulin G1κ subclass directed against soluble and membrane-bound interleukin-6 (IL-6) receptor (IL-6R) which plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. -
CAS-Nummer
- 375823-41-9
Target
-
